TScan Therapeutics (TCRX) Accounts Payables (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Accounts Payables data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 53.62% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 53.62% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 70.99% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.3 million, up from $1.2 million in the prior quarter.
• Over the last five years, Accounts Payables for TCRX reached as high as $6.4 million in Q3 2025 and fell as low as $1.2 million in Q4 2025.
• Historically, Accounts Payables has averaged $3.3 million across 5 years, with a median of $3.1 million in 2022.
• On a YoY basis, Accounts Payables climbed as much as 133.91% in 2025 and fell as far as 70.99% in 2025.
• Year by year, Accounts Payables stood at $2.9 million in 2022, then retreated by 18.48% to $2.4 million in 2023, then surged by 80.2% to $4.3 million in 2024, then sank by 70.99% to $1.2 million in 2025, then soared by 85.58% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.3 million in Q1 2026, $1.2 million in Q4 2025, and $6.4 million in Q3 2025.